NBY NovaBay Pharmaceuticals Inc.: Net earnings per share for the last four quarters

Official company branding of NovaBay Pharmaceuticals Inc. (NBY)

The 12-month annual growth in earnings per share demonstrates the development dynamics of NovaBay Pharmaceuticals (NBY), where 96.70 characterizes this valuation parameter. The issuer is betting on Avenova brand recognition and the expansion of DTC sales. The absence of geopolitical threats in the US stabilizes the business, while final revenues are based on demand for eyelid hygiene products and the operational efficiency of ophthalmology networks.

NBY: NovaBay Earnings per share for the last twelve months 02/11/2024 - 04/18/2026

NovaBay Pharmaceuticals - analytical breakdowns and key metrics (NBY)

Fundamental company valuation:NovaBay Pharmaceuticals Inc. - NBY
Flagship merchandise of NovaBay

Earnings per share dynamics determine the fundamental value of NovaBay Pharmaceuticals (NBY), serving as an indicator of business scaling efficiency. By analyzing the YoY EPS change on a rolling 12-month basis, an investor tracks net income growth rates relative to the previous year, which is currently critical for assessing the success of the strategy to reduce reliance on a single brand through the launch of new product lines.

Competitor analysis for NovaBay Pharmaceuticals

Net earnings per one share for the last twelve months Alcon Inc|BLCO: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Glaukos Medical (GKOS)|Earnings per share for the last twelve months apellis.com|Belite Bio (BLTE) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Ocular Pharma (OCUL)|HROW (Harrow) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) VRDN (Viridian Corp)|LENZ Corp (LENZ) - Net earnings per one share for the last twelve months|OCS: Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months eyepointpharma.com|KOD: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Aldeyra Therapeutics (ALDX)|Net earnings per share for the last 12 months KALA|IRD - Net earnings per share for the trailing year|Earnings per share for the last twelve months okyopharma.com (OKYO)|Net earnings per share (EPS TTM) Adverum Biotechnologies Inc. (ADVM)|Earnings per share for the last twelve months outlooktherapeutics.com OTLK|Net earnings per share for the last four quarters Clearside Biomedical, Inc. (CLSD)|Kiora Pharmaceuticals, Inc. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year ALIM (Alimera Sciences, Inc.)|EYEN (Eyenovia Corp) - Net earnings per share for the last 12 months|Guardion Health Science - Earnings per share for the trailing year|Earnings per share for the last twelve months Ocuphire Pharma, Inc.|Opthea Ltd. (OPT) - Net earnings per share for the last four quarters